Skip to content

Dott.ssa Varano Monica

Direttore Scientifico
Dott.ssa Varano Monica

Pubblicazioni scientifiche: PubMed

Principali specializzazioni: Degenerazione maculare legata all'età, Ipovisione e Riabilitazione Visiva, Occlusione Venosa Retinica, Patologia Maculare d'interesse chirurgico, Retinopatia Diabetica

Attività medica: opera presso la sede della Fondazione G.B. Bietti in Via Livenza 3, Roma

  • 1984 Laurea in medicina e chirurgia (110/110 con lode) Universita’ “La Sapienza”, Rome
  • 1988 Specializzazione in in Oftalmologia  (70/70 con lode) Universita’ “La Sapienza”, Rome
  • 1989 Vincitrice di borsa di studio della  Fondazione G.B.Bietti
  • 1993 Frequenza presso il Dipartimento  of Laser and Angiografia  of Universita’ of Creteil, Paris, Director Prof. Gabriel Coscas
  • Dal 1991 al  2005 Ricercatore  nel Dipartimento di Retina medica  della Fondazione Bietti
  • Dal 2005 al 2014 Ricercatore di ruolo, Responsabile Unità Operativa Retina Medica Fondazione G.B. Bietti-IRCCS
  • Dal 2008 al 2014 Responsabile del centro delle maculopatie  Fondazione G.B. Bietti-IRCCS, presso il presidio Britannico  – ASL S. Giovanni Addolorata”, Via Santo Stefano Rotondo n 6-00184 Rome, Italy
  • Dal settembre 2014 Direttore scientifico  IRCCS Fondazione G.B. Bietti
  • Dal 2016 Docente Universita’ “Tor Vergata” di Roma e Università “Campus Biomedico” di  Roma

  • 1998 – 2007  Membro Comitato scientifico della S.I.R. (Società italiana della Retina)
  • 2008 Participatione alla stesura delle “Linee guida italiane della degenerazione maculare legata all’età”
  • 2008 Principal investigator in the research project aims for 2008 “identification of genetic determinants of diabetic retinopathy in patients with type 2 diabetes”
  • 2009 Principal investigator in the research project aims for 2009 “Biomarkers of inflammation and innate immunity in diabetic retinopathy”
  • 2009 Participatione alla stesura del “Consensus Document Italian on Medical Therapy and Prevention of Age-related Macular Degeneration (AMD )”
  • 2009 Professore of the Master in vitreo-retina. Polytechnic Univesity of Marche
  • 2010 Participatione alla stesura  del “Consensus Document for Retinal Venous Occlusions”
  • 2011 Presidente della S.I.R. (Società italiana della Retina)
  • 2011 Professor of the Master of second level . “Vitreoretinal pathology : from diagnosis to medical and surgical therapy ,” Catholic University of Rome in 2011″
  • Dal 2012 fa parte del gruppo  di lavoro “Complicanze oculari del diabete” del SID (Societa’ italiana di diabetologia)
  • 2012-2013 Participatione alla stesura delle “Linee guida italiane della retinopatia diabetica”
  • 2013 Participatione alla stesura  del “Consensus document for the diagnosis and clinical management of vitreo macular traction”
    Docente di circa 200 corsi e congressi, principalmente su diagnosi funzionale e morfologica, trattamento laser e PDT , terapia antiangiogenica delle malattie vascolari e degenerative della corio retina
  • Dal 1990 Società Oftalmologica Italiana (Italian Society of Ophthalmology)
  • Dal 1998 Italian Society of Retina (SIR)
  • Dal 2000 The Association for Research in Vision and Ophthalmology (ARVO)
  • Dal 2002 Jules Gonin Club
  • Dal 2006 American Academy of Ophthalmology
  • An open-label , multicenter study of the treatment of predominantly classic subfoveal  choroidal neovascularization secondary to age–related macular degeneration using photodynamic therapy with Verteporfin in Italy (VIT)
  • Open label multicenter randomized case-control clinical trial to evaluate the efficacy  of the antioxidant therapy with Azyr in theearly age related macular degeneration
  • A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion
  • A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. (Mead)
  • A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (Montblanc)
  • A 12  Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis (Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD. (Luvi)
  • A randomized, double masked , active controlled , phase 3 study of the efficacy , safety and tolerability of repeteated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD)
  • A phase II  prospective , randomised , multicentric diabetic macular edema  dose ranging , comparation study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS)
  • A randomized, double-masked, sham controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trat-Eye in subjects with macular edema secondary to central vein occlusion (CRVO) (GALILEO)
  • A Clinical Safety and Efficacy Comparison of  NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients (MIZAR)
  • A 2 years randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efiicacy and safety of 0.5 mg ranibizumab in two “treat and axtend” Treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to Diabetes mellitus (RETAIN)
  • A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreale VEGF Trap-Eye in subjects with diabetic macular edema (VIVID)
  • A 12 month, multicentre, randomized parallel group study to compare the efficacy and safety of Ozurdex versus Lucentis in patients with branch retinal vein occlusion. (COMO)
  • A 6-month, phase II, double masked, multicentre, randomized Placebo- controlled parallel group study to asses the safety and efficacy of topical administration of two concentration of FOV2304 (1% and 2%) twice daily for the treatment of center involving clinically significant macular edema associated with Diabetic Retinopaty  (FOVEA)
  • Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non invasive procedures. (EVI)
  • A multicentric open-label randomized study comparing the efficacy and safety of 700  g dexamethasone segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema (LUZO)
  • An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. (CRFB002DIT01- PRIDE)
  • A retrospective non-interventional  study to assess the effectiveness of existing Anti‑vascUlar endothelial growth factor (anti‑VEGF) treatment  Regimens in patients with wet Age-related macular degeneration (Aura)
  • A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration” CRFB002A2411 (Trend)
  • A 12-month, randomized, double-masked, sham-controlled,multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor(VEGF) driven choroidal neovascularization (CNV) (Minerva)
  • Prospective, randomized, multicenter, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus and PRP in monotherapy in the treatment of patients with high risk proliferative diabetic retinopathy. (PROTEUS)
  • A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess the effectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens (Polaris)
  • A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (Olimpic)
  • A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration. (Fovista)
  • Studio interventistico, multicentrico, prospettico, in aperto, con un solo gruppo di trattamento, della durata di 12 mesi per valutare la sicurezza e la  tollerabilità di ranibizumab 0.5 mg in pazienti affetti da wAMD mono/bilaterale in occhi con BCVA inferiore a 2/10 e/o patologia del  secondo occhio (Tweyes)
  • Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction(symptomatic Vitreomacular Adhesion)
  • A Collaborative Retrospective trial on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES)
  • Phase III, Multi-center, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of Lampalizumab ITV Injections Administered Monthly for 24 Months in Patients with Geographic Atrophy Secondary to AMD
  • Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin)
  • A multi-center, single-arm, interventional phase IV study to evaluate the management of Central Retinal Vein Occlusion (CRVO) using a Treat and Extend Regimen of Intra-vitreal Aflibercept (CENTERA)
  • British Journal of Ophthalmology
  • Retinal Cases & Brief Reports
  • Archives of Ophthalmology
  • Retina
  • European Journal of ophthalmology
  • BMC Ophthalmology
  • International Journal of Ophthalmology
  • Basic & Clinical Pharmacology & Toxicology
  • BioMed Research International
    • Vincitore progetto ricerca finalizzata 2008 Ministero della salute “identification of genetic determinants of diabetic retinopathy in patients with type 2 diabetes”
    • Vincitore progetto ricerca finalizzata 2009 Ministero della salute “Biomarkers of inflammation and innate immunity in diabetic retinopathy”
    • Best Paper SOI 2017
    Skip to content